ECSP099681A - Formas sólidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il) etanona oxima - Google Patents
Formas sólidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il) etanona oximaInfo
- Publication number
- ECSP099681A ECSP099681A EC2009009681A ECSP099681A ECSP099681A EC SP099681 A ECSP099681 A EC SP099681A EC 2009009681 A EC2009009681 A EC 2009009681A EC SP099681 A ECSP099681 A EC SP099681A EC SP099681 A ECSP099681 A EC SP099681A
- Authority
- EC
- Ecuador
- Prior art keywords
- imidazol
- tetrahydroxibute
- etanona
- oxima
- solid forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen formas sólidas amorfas y cristalinas de (E)-M-(4-((1R,2S,3R)-1,2,3,4-tetrahidroxibutil)-1H-imidazol-2-il)-etanona oxima. Estas formas sólidas específicas se pueden utilizar como moduladores fosfato de esfingosita-1 para tratar enfermedades autoinmunes e inflamatorias.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92303707P | 2007-04-12 | 2007-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP099681A true ECSP099681A (es) | 2009-12-28 |
Family
ID=39639233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2009009681A ECSP099681A (es) | 2007-04-12 | 2009-10-07 | Formas sólidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il) etanona oxima |
Country Status (23)
Country | Link |
---|---|
US (2) | US20080275099A1 (es) |
EP (1) | EP2139865B1 (es) |
JP (1) | JP5496080B2 (es) |
KR (1) | KR20100015464A (es) |
CN (1) | CN101284818B (es) |
AR (1) | AR065979A1 (es) |
AU (1) | AU2008240255B2 (es) |
BR (1) | BRPI0810197A2 (es) |
CA (1) | CA2683963A1 (es) |
CL (1) | CL2008001043A1 (es) |
CO (1) | CO6230981A2 (es) |
EA (1) | EA017042B1 (es) |
EC (1) | ECSP099681A (es) |
ES (1) | ES2453543T3 (es) |
HK (1) | HK1124851A1 (es) |
IL (1) | IL201037A (es) |
MX (1) | MX2009010904A (es) |
NZ (1) | NZ579689A (es) |
PE (1) | PE20090072A1 (es) |
TW (1) | TWI412362B (es) |
UY (1) | UY31012A1 (es) |
WO (1) | WO2008128045A1 (es) |
ZA (1) | ZA200906493B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7649098B2 (en) * | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
TW200848029A (en) | 2007-03-01 | 2008-12-16 | Lexicon Pharmaceuticals Inc | Heterocyclic compounds, compositions comprising them and methods of their use |
AR065980A1 (es) | 2007-04-12 | 2009-07-15 | Lexicon Pharmaceuticals Inc | Metodos para preparar compuestos basados en imidazol |
TW200920355A (en) * | 2007-09-06 | 2009-05-16 | Lexicon Pharmaceuticals Inc | Compositions and methods for treating immunological and inflammatory diseases and disorders |
ES2401555T3 (es) * | 2008-06-18 | 2013-04-22 | Lexicon Pharmaceuticals, Inc. | Formas sólidas de (1R,2S,3R)-1-(2-(isoxazol-3-il)-1H-imidazol-4-il)butano-1,2,3,4-tetraol y métodos de utilización de las mismas |
WO2011102404A1 (ja) | 2010-02-18 | 2011-08-25 | 第一三共株式会社 | イミダゾール誘導体 |
EP2586874B1 (en) | 2010-06-28 | 2015-04-22 | Daiichi Sankyo Company, Limited | Method for screening for s1p lyase inhibitor using cultured cell |
WO2013002248A1 (ja) | 2011-06-28 | 2013-01-03 | 第一三共株式会社 | リン酸エステル誘導体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4567194A (en) | 1983-03-10 | 1986-01-28 | The Coca-Cola Company | 2-Acylimidazole compounds, their synthesis and use as medicinal agents |
AU2881797A (en) * | 1996-05-31 | 1998-01-05 | University Of Wollongong, The | Acetyl derivatives of thiazoles and analogues |
CN101395141A (zh) * | 2006-02-24 | 2009-03-25 | 莱西肯医药有限公司 | 咪唑基化合物,包含其的组合物和它们的使用方法 |
US7649098B2 (en) * | 2006-02-24 | 2010-01-19 | Lexicon Pharmaceuticals, Inc. | Imidazole-based compounds, compositions comprising them and methods of their use |
AR065980A1 (es) * | 2007-04-12 | 2009-07-15 | Lexicon Pharmaceuticals Inc | Metodos para preparar compuestos basados en imidazol |
-
2008
- 2008-03-18 TW TW097109517A patent/TWI412362B/zh active
- 2008-04-08 AR ARP080101445A patent/AR065979A1/es unknown
- 2008-04-08 UY UY31012A patent/UY31012A1/es not_active Application Discontinuation
- 2008-04-11 NZ NZ579689A patent/NZ579689A/en unknown
- 2008-04-11 MX MX2009010904A patent/MX2009010904A/es active IP Right Grant
- 2008-04-11 KR KR1020097021116A patent/KR20100015464A/ko not_active Application Discontinuation
- 2008-04-11 BR BRPI0810197-3A2A patent/BRPI0810197A2/pt not_active IP Right Cessation
- 2008-04-11 WO PCT/US2008/060036 patent/WO2008128045A1/en active Application Filing
- 2008-04-11 EP EP08745612.5A patent/EP2139865B1/en active Active
- 2008-04-11 PE PE2008000640A patent/PE20090072A1/es not_active Application Discontinuation
- 2008-04-11 JP JP2010503233A patent/JP5496080B2/ja active Active
- 2008-04-11 ES ES08745612.5T patent/ES2453543T3/es active Active
- 2008-04-11 CL CL200801043A patent/CL2008001043A1/es unknown
- 2008-04-11 EA EA200970940A patent/EA017042B1/ru not_active IP Right Cessation
- 2008-04-11 CA CA002683963A patent/CA2683963A1/en not_active Abandoned
- 2008-04-11 AU AU2008240255A patent/AU2008240255B2/en active Active
- 2008-04-11 CN CN2008100870964A patent/CN101284818B/zh active Active
- 2008-04-11 US US12/101,445 patent/US20080275099A1/en not_active Abandoned
-
2009
- 2009-03-19 HK HK09102666.0A patent/HK1124851A1/xx unknown
- 2009-08-06 US US12/536,714 patent/US8658682B2/en active Active
- 2009-09-17 IL IL201037A patent/IL201037A/en active IP Right Grant
- 2009-09-17 ZA ZA2009/06493A patent/ZA200906493B/en unknown
- 2009-10-07 EC EC2009009681A patent/ECSP099681A/es unknown
- 2009-10-09 CO CO09112459A patent/CO6230981A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20080275099A1 (en) | 2008-11-06 |
TW200848027A (en) | 2008-12-16 |
ZA200906493B (en) | 2010-11-24 |
EP2139865B1 (en) | 2014-01-01 |
BRPI0810197A2 (pt) | 2014-12-30 |
WO2008128045A8 (en) | 2010-01-21 |
CL2008001043A1 (es) | 2008-09-26 |
CN101284818A (zh) | 2008-10-15 |
EA200970940A1 (ru) | 2010-02-26 |
WO2008128045A1 (en) | 2008-10-23 |
IL201037A (en) | 2015-08-31 |
US8658682B2 (en) | 2014-02-25 |
PE20090072A1 (es) | 2009-02-18 |
IL201037A0 (en) | 2010-05-17 |
JP2010523707A (ja) | 2010-07-15 |
CA2683963A1 (en) | 2008-10-23 |
AU2008240255A1 (en) | 2008-10-23 |
JP5496080B2 (ja) | 2014-05-21 |
EA017042B1 (ru) | 2012-09-28 |
KR20100015464A (ko) | 2010-02-12 |
NZ579689A (en) | 2011-10-28 |
ES2453543T3 (es) | 2014-04-08 |
AR065979A1 (es) | 2009-07-15 |
AU2008240255B2 (en) | 2013-07-04 |
UY31012A1 (es) | 2008-09-02 |
CO6230981A2 (es) | 2010-12-20 |
EP2139865A1 (en) | 2010-01-06 |
HK1124851A1 (es) | 2009-07-24 |
US20090298901A1 (en) | 2009-12-03 |
TWI412362B (zh) | 2013-10-21 |
MX2009010904A (es) | 2009-10-26 |
CN101284818B (zh) | 2012-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP099681A (es) | Formas sólidas de (e)-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il) etanona oxima | |
TN2009000388A1 (en) | 3-imidazolyl-indoles for the treatment of proliferative diseases | |
RS53124B (en) | USE OF BETANECOL FOR THE TREATMENT OF XEROSOMOMY | |
CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
GT201000015A (es) | Sulfonamidas como moduladores de trpms | |
MA32562B1 (fr) | Composes organiques pour la cicatrisation de lesion | |
CR20140334A (es) | Forma galénica divisible que permite una liberación modificada del principio activo | |
EP2350129A4 (en) | PD1 Antagonist Compositions and Methods for their Use | |
CR11488A (es) | 4-fenilpiran 3,5-dionas, 4-feniltiopiran-3,5-dionas y 2-fenilciclohexan-1,3,5-trionas como herbicidas | |
MX366318B (es) | Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1. | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA200901621A1 (ru) | Индукция толерогенного фенотипа у зрелых дендритных клеток | |
WO2012106281A3 (en) | Multimodal trail molecules and uses in cellular therapies | |
HN2011001446A (es) | Compuesto utiles para inhibir chk1 | |
EA201070447A1 (ru) | Способ обработки волос | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
DK3135672T3 (da) | Sammensætninger og fremgangsmåder til behandling af alkoholforbrugslidelser, smerter og andre sygdomme | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
ECSP099675A (es) | Compuestos heterocíclicos, composición y métodos de uso | |
CR20110660A (es) | Mezclas fungicidas | |
CR20130106A (es) | Nuevos moduladores de trpv3 | |
ES2525137R2 (es) | Agentes para tratar el mieloma múltiple | |
CR20110010A (es) | Formulaciones que tienen una compatibilidad mejorada con sustratos no tejidos | |
GT200900045A (es) | Sales de bencimidazolilo piridilo eteres y las formulaciones del mismo | |
GT200800052A (es) | Compuestos triciclicos utiles como agonistas de recepciones de oxitocina |